Skip to Content
Merck
  • Bafilomycin A1 enhances NLRP3 inflammasome activation in human monocytes independent of lysosomal acidification.

Bafilomycin A1 enhances NLRP3 inflammasome activation in human monocytes independent of lysosomal acidification.

The FEBS journal (2020-11-05)
Shi Yu, Jack Green, Rose Wellens, Gloria Lopez-Castejon, David Brough
ABSTRACT

The release of interleukin (IL)-1β from primary human monocytes in response to extracellular LPS occurs through the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome. In primary monocytes, in response to LPS, NLRP3 inflammasome activation is characterized by an independence of K+ efflux and ASC speck formation and has been termed the 'alternative' pathway. Here, we report that pharmacological inhibition of V-ATPase with bafilomycin A1 exacerbated LPS-induced NLRP3 inflammasome activation in primary human monocytes. Inhibition of V-ATPase in the presence of extracellular LPS led to NLRP3-dependent, K+ efflux-independent, ASC oligomerization and caspase-1 activation. Although V-ATPases are required for lysosomal acidification, we found that acidic lysosomal pH and protease activity were dispensable for this altered response, suggesting that V-ATPase inhibition triggered alternative signalling events. Therefore, V-ATPases may serve additional roles during NLRP3 inflammasome activation in primary human monocytes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O26:B6, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Peptidoglycan from Staphylococcus aureus, cell wall component
Sigma-Aldrich
Nigericin sodium salt, ≥98% (TLC)
Sigma-Aldrich
Bafilomycin A1 from Streptomyces griseus, ≥90% (HPLC)
Sigma-Aldrich
Anti-β-Actin−Peroxidase antibody, Mouse monoclonal, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
U 18666A, powder
Sigma-Aldrich
Dimethyl sulfoxide, ACS reagent, ≥99.9%